CONCLUSION:: In a cohort of pregnant patients treated with either methadone or buprenorphine and naloxone in pregnancy, newborns exposed to maternal buprenorphine and naloxone had less frequent neonatal abstinence syndrome. Additionally, neonates exposed to buprenorphine and naloxone had shorter overall hospitalization lengths. LEVEL OF EVIDENCE:: II.
PMID: 25569005 [PubMed – as supplied by publisher] (Source: Obstetrics and Gynecology)

CONCLUSIONS: In the United States opioid use and related unintentional lethal overdoses continue to rise, particularly in rural areas. Increasing access to office-based treatment of opioid use disorder-particularly in rural America-is a promising strategy to address rising rates of opioid use disorder and unintentional lethal overdoses.
PMID: 25583888 [PubMed – in process] (Source: Annals of Family Medicine)

CONCLUSIONS: The use of buprenorphine products to treat opioid dependence has increased significantly in the past 10 years and has shifted to greater use by primary care physicians, indicating a rapidly changing face of opioid maintenance therapy in the United States. (Am J Addict 2015;24:24-29).
PMID: 25823632 [PubMed – in process] (Source: The American Journal on Addictions)

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals)

One of the top outpatient Suboxone detox centers, Complete Care Medical Center, is now offering same week appointments with licensed specialists. The Center offers multiple licensed Suboxone doctors…(PRWeb December 28, 2014)Read the full story at http://www.prweb.com/releases/suboxone-doctor/fort-lauderdale-fl/prweb12416438.htm (Source: PRWeb: Medical Pharmaceuticals)

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence)

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence)

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care expenditures based on current market shares of Bup/Nal film and generic Bup/Nal tablet. (Source: Drug and Alcohol Dependence)